Systematic literature review of the signs and symptoms of respiratory syncytial virus

• Published in: Influenza and other respiratory viruses Vol. 17; no. 2; pp. e13100 - n/a
• Main Authors: Colosia, Ann, Costello, Jessica, McQuarrie, Kelly, Kato, Kelly, Bertzos, Kristi
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.02.2023; John Wiley and Sons Inc
• Subjects: Adolescent; Adolescents; Adults; Aged; Child; Child, Preschool; Children; Chronic obstructive pulmonary disease; Comorbidity; Cough; Dyspnea; FDA approval; Fever; Hospitalization; Humans; Infant; Influenza; Length of stay; Older people; Palivizumab; pediatrics; Qualitative research; Respiratory diseases; respiratory infection; Respiratory syncytial virus; Respiratory Syncytial Virus Infections - diagnosis; Respiratory Syncytial Virus Infections - epidemiology; Respiratory Syncytial Virus, Human; Respiratory tract; Respiratory tract diseases; Respiratory Tract Infections; Risk; Risk groups; signs; Signs and symptoms; Sputum; symptoms; Systematic Review; Systematic Reviews; Vaccines; Viruses; United States > US; symptoms; signs; respiratory syncytial virus; adults; pediatrics; respiratory infection
• ISSN: 1750-2640; 1750-2659
• DOI: 10.1111/irv.13100

Respiratory syncytial virus (RSV) is responsible for over 30 million lower respiratory tract infections (LRTIs) and 3 million hospitalizations worldwide each year. Despite the risk RSV poses to young children, older adults, and individuals with comorbidities or suppressed immunity, there is limited understanding of RSV symptom presentation across these at‐risk groups, and there is no vaccine for RSV. We conducted two systematic literature reviews (SLRs) of studies that document signs and symptoms (S&S) of RSV in (1) children aged ≤5 years and (2) immunocompromised adolescents and adults, and adults at high risk for severe RSV due to age or comorbidities. Symptom duration and hospital length of stay (LOS) were explored. Electronic database searches were performed following PRISMA guidelines. Studies captured RSV S&S across community and hospital settings. Clinicians and caregivers reported (n = 25 studies) nasal discharge/congestion, cough, shortness of breath, feeding abnormalities, and fever in ≥40% of children across studies and settings. Median hospital stays for children ranged from 2 days in the United States to 7.5 days in China. High‐risk adults with RSV (n = 6 studies) commonly (≥40% of adults) reported cough, sputum, dyspnea, and fever/feverishness. Median length of hospital stay in adults ranged from 6 to 15 days across studies. Caregivers and clinicians reported similar RSV S&S in young children, including upper and lower respiratory and systemic symptoms. In high‐risk and immunocompromised adults, the most frequent (in multiple publications) and commonly reported RSV S&S were primarily LRTI symptoms. RSV symptoms could last for weeks and are variable based on geography.